| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... The Lancet 372 (9637), 449-456, 2008 | 3712 | 2008 |
| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 2820 | 2019 |
| Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open … T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ... The Lancet Oncology 21 (12), 1563-1573, 2020 | 603 | 2020 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 534* | 2021 |
| Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery K Bensalah, AJ Pantuck, N Rioux-Leclercq, R Thuret, F Montorsi, ... European urology 57 (3), 466-473, 2010 | 333 | 2010 |
| Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGFβ signaling C Ringuette Goulet, G Bernard, S Tremblay, S Chabaud, S Bolduc, ... Molecular Cancer Research 16 (7), 1196-1204, 2018 | 265 | 2018 |
| Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling CR Goulet, A Champagne, G Bernard, D Vandal, S Chabaud, F Pouliot, ... BMC cancer 19, 1-13, 2019 | 238 | 2019 |
| A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer … KJ Pienta, MA Gorin, SP Rowe, PR Carroll, F Pouliot, S Probst, ... The Journal of urology 206 (1), 52-61, 2021 | 231 | 2021 |
| Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ... Clinical Cancer Research 27 (13), 3674-3682, 2021 | 231 | 2021 |
| Contemporary management of renal tumors with venous tumor thrombus F Pouliot, B Shuch, JC LaRochelle, A Pantuck, AS Belldegrun The Journal of urology 184 (3), 833-841, 2010 | 204 | 2010 |
| CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy J Escamilla, S Schokrpur, C Liu, SJ Priceman, D Moughon, Z Jiang, ... Cancer research 75 (6), 950-962, 2015 | 194 | 2015 |
| Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non–clear cell renal cell carcinoma DF McDermott, JL Lee, M Ziobro, C Suarez, P Langiewicz, VB Matveev, ... Journal of Clinical Oncology 39 (9), 1029, 2021 | 156 | 2021 |
| A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis T Azad, HJ Janse van Rensburg, ED Lightbody, B Neveu, A Champagne, ... Nature communications 9 (1), 1061, 2018 | 141 | 2018 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of … BI Rini, ER Plimack, V Stus, T Waddell, R Gafanov, F Pouliot, D Nosov, ... Journal of Clinical Oncology 39 (15_suppl), 4500-4500, 2021 | 124 | 2021 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor … BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... Journal of Clinical Oncology 37 (15_suppl), 4500-4500, 2019 | 123 | 2019 |
| Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma: results from cohort A of KEYNOTE-427 DF McDermott, JL Lee, C Szczylik, F Donskov, J Malik, BY Alekseev J Clin Oncol 36 (Suppl. 15_suppl), 4500, 2018 | 122 | 2018 |
| Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells F Pouliot, A Blais, C Labrie Cancer research 63 (2), 277-281, 2003 | 118 | 2003 |
| Role of Smad1 and Smad4 proteins in the induction of p21 WAF1, Clp1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells F Pouliot, C Labrie Journal of endocrinology 172 (1), 187-198, 2002 | 111 | 2002 |
| SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. C COVIDSurg, C GlobalSurg Anaesthesia 77 (1), 28-39, 2022 | 100 | 2022 |
| Is routine renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses? PO Richard, LT Lavallée, F Pouliot, M Komisarenko, L Martin, JB Lattouf, ... The Journal of urology 200 (4), 731-736, 2018 | 92 | 2018 |
